Glaukos Corporation (GKOS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GKOS SEC filings page.
Glaukos Corporation (GKOS) reported $612.8M in revenue over the twelve months to Jun 30, 2026, up 41.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expansion is being absorbed by a sharp gross-margin reset, while cash losses improve far faster than reported earnings.
Earnings and cash flow diverged materially in FY2025: net loss widened to-$187.7M from-$146.4M , yet operating cash outflow narrowed to-$14.8M from-$61.3M . That gap suggests reported profitability is being weighed down by non-cash or timing effects, although the business still did not convert accounting activity into positive operating cash.
Revenue grew 32.3% to
Operating expenses outpaced gross-profit capacity: selling, general and administrative expense reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Glaukos Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Glaukos Corporation has an operating margin of -39.3%, meaning the company loses $39 on every $100 of revenue. This results in a profitability score of 24/100. This is down from -31.9% the prior year.
Glaukos Corporation's revenue surged 32.3% year-over-year to $507.4M, reflecting rapid business expansion. This strong growth earns a score of 88/100.
Glaukos Corporation carries a low D/E ratio of 0.36, meaning only $0.36 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.69, Glaukos Corporation holds $4.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 91/100.
Glaukos Corporation's operations used $14.8M of cash, and capex of $7.7M added to the outflow, for a free cash flow shortfall of $22.5M. This results in a cash flow score of 11/100.
Glaukos Corporation posts a -28.6% return on equity (ROE), meaning it loses $29 for every $100 of shareholders' equity. This results in a returns score of 24/100. This is down from -19.1% the prior year.
Glaukos Corporation scores 23.81, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($9.9B) relative to total liabilities ($237.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Glaukos Corporation passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Glaukos Corporation reported a net loss of $187.7M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Glaukos Corporation reported an operating loss of $199.6M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Glaukos Corporation generated $185.6M in revenue in Q2 2026. This represents an increase of 49.5% from the same quarter a year earlier. Against the prior quarter it is up 23.3%.
Glaukos Corporation's EBITDA was -$8.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 40.5% from the same quarter a year earlier. Against the prior quarter it is down 4.2%.
Glaukos Corporation reported -$18.4M in net income in Q2 2026. This represents an increase of 6.5% from the same quarter a year earlier. Against the prior quarter it is up 7.1%.
Glaukos Corporation earned -$0.31 per diluted share (EPS) in Q2 2026. This represents an increase of 8.8% from the same quarter a year earlier. Against the prior quarter it is up 8.8%.
Cash & Balance Sheet
Glaukos Corporation generated $12.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 108.4% from the same quarter a year earlier. Against the prior quarter it is up 173.3%.
Glaukos Corporation held $114.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Glaukos Corporation's gross margin was 81.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.
Glaukos Corporation's operating margin was -9.3% in Q2 2026, reflecting core business profitability. This is up 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.9 percentage points.
Glaukos Corporation's net profit margin was -9.9% in Q2 2026, showing the share of revenue converted to profit. This is up 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.2 percentage points.
Glaukos Corporation's ROE was -2.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.
Capital Allocation
Glaukos Corporation invested $51.3M in research and development in Q2 2026. This represents an increase of 40.4% from the same quarter a year earlier. Against the prior quarter it is up 16.2%.
Glaukos Corporation invested $2.7M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 132.2% from the same quarter a year earlier. Against the prior quarter it is down 30.8%.
Not reported for Q2 2026.
GKOS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $185.6M+49.5% | $150.6M+41.2% | $143.1M+35.7% | $133.5M+38.1% | $124.1M+29.7% | $106.7M+24.6% | $105.5M+28.1% | $96.7M+23.9% |
| Cost of Revenue | $34.0M+26.5% | $33.3M+37.1% | $31.8M+11.0% | $28.8M+27.7% | $26.9M+19.3% | $24.3M+20.0% | $28.6M+51.6% | $22.6M+22.0% |
| Gross Profit | $151.6M+55.9% | $117.2M+42.4% | $111.3M+44.9% | $104.7M+41.3% | $97.2M+32.9% | $82.3M+26.0% | $76.9M+21.1% | $74.1M+24.4% |
| R&D Expenses | $51.3M+40.4% | $44.1M+36.4% | $43.7M+19.5% | $38.1M+9.6% | $36.5M+6.1% | $32.4M+5.3% | $36.5M-1.4% | $34.7M+4.3% |
| SG&A Expenses | $116.1M+39.2% | $92.9M+31.5% | $94.7M+37.2% | $83.0M+29.7% | $83.4M+26.0% | $70.7M+14.0% | $69.0M+9.5% | $64.0M+18.0% |
| Operating Income | -$17.3M+23.9% | -$19.9M+4.0% | -$139.9M-387.9% | -$16.4M+33.6% | -$22.7M+24.3% | -$20.7M+47.1% | -$28.7M+25.8% | -$24.7M+12.0% |
| EBITDA | -$8.4M+40.5% | -$8.1M+35.3% | -$127.7M-540.9% | -$7.2M+53.8% | -$14.1M+32.7% | -$12.5M+58.7% | -$19.9M+33.8% | -$15.7M+19.9% |
| Interest Expense | $1.5M+26.8% | $1.1M-3.3% | $1.1M-27.1% | $1.2M-29.3% | $1.2M-65.7% | $1.2M-66.3% | $1.6M-54.1% | $1.7M-51.1% |
| Income Tax | $656K+164.5% | $484K+48.5% | -$6.2M-5302.6% | $234K+32.2% | $248K-25.1% | $326K-13.5% | -$114K-286.9% | $177K+378.4% |
| Net Income | -$18.4M+6.5% | -$19.8M-9.0% | -$133.7M-298.0% | -$16.2M+24.2% | -$19.7M+61.1% | -$18.1M+55.6% | -$33.6M+8.7% | -$21.4M+29.7% |
| EPS (Basic) | -$0.31+8.8% | -$0.34-6.3% | -$2.33-294.9% | -$0.28+28.2% | -$0.34+66.0% | -$0.32+61.0% | -$0.59+21.3% | -$0.39+38.1% |
| EPS (Diluted) | -$0.31+8.8% | -$0.34-6.3% | -$2.33-294.9% | -$0.28+28.2% | -$0.34+66.0% | -$0.32+61.0% | -$0.59+21.3% | -$0.39+38.1% |
| Diluted Shares (Avg) | 59M+2.8% | 58M+2.4% | N/A | 57M+4.3% | 57M+12.8% | 57M+14.2% | N/A | 55M+13.1% |
GKOS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $920.5M-6.7% | $893.3M-7.5% | $893.5M-8.3% | $999.4M+7.9% | $987.0M+7.3% | $966.2M+3.5% | $974.8M+3.7% | $926.5M-2.3% |
| Current Assets | $515.8M+18.3% | $485.8M+9.3% | $475.0M+5.6% | $454.8M+14.5% | $436.1M+13.6% | $444.5M+14.4% | $449.8M+13.7% | $397.3M-0.6% |
| Cash & Equivalents | $114.5M+13.6% | $104.2M-8.8% | $90.8M-46.5% | $98.2M-1.9% | $100.8M+48.1% | $114.3M+168.9% | $169.6M+81.5% | $100.1M-8.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $59.3M-8.2% | $62.4M+4.9% | $63.6M+10.2% | $63.9M+6.6% | $64.6M+14.4% | $59.5M+18.5% | $57.7M+37.4% | $59.9M+50.6% |
| Accounts Receivable | $138.9M+67.4% | $119.7M+67.3% | $108.6M+78.8% | $98.7M+74.9% | $83.0M+62.0% | $71.5M+53.7% | $60.7M+52.4% | $56.4M+43.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $66.7M0.0% | $66.7M+0.9% | $66.7M+0.9% | $66.7M+0.9% | $66.7M+0.9% | $66.1M0.0% | $66.1M0.0% | $66.1M0.0% |
| Total Liabilities | $238.0M+7.3% | $222.4M+10.0% | $237.3M+14.2% | $229.8M-10.9% | $221.8M-12.8% | $202.2M-58.1% | $207.8M-56.6% | $258.0M-45.2% |
| Current Liabilities | $102.3M+29.3% | $89.4M+30.5% | $101.3M+34.8% | $87.5M+22.1% | $79.1M+12.9% | $68.5M-5.1% | $75.1M+1.5% | $71.7M+6.8% |
| Non-Current Liabilities | $135.7M-4.9% | $133.0M-0.5% | $136.1M+2.5% | $142.3M-23.6% | $142.7M-22.6% | $133.7M-67.4% | $132.7M-67.2% | $186.3M-53.9% |
| Total Equity | $682.5M-10.8% | $670.9M-12.2% | $656.2M-14.4% | $769.5M+15.1% | $765.1M+15.0% | $764.0M+69.5% | $766.9M+66.1% | $668.5M+40.0% |
| Retained Earnings | -$971.3M-24.0% | -$952.9M-24.8% | -$933.1M-25.2% | -$799.5M-12.3% | -$783.2M-13.4% | -$763.6M-19.3% | -$745.4M-24.4% | -$711.9M-26.6% |
Not reported in any period shown, so not listed: Long-Term Debt.
GKOS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $14.8M+112.4% | -$12.5M+32.4% | $6.8M+1249.7% | -$10.1M-5.3% | $7.0M+138.0% | -$18.5M+45.3% | $507K+104.8% | -$9.6M-17.4% |
| Depreciation & Amortization | $8.9M+3.5% | $11.8M+43.4% | $12.2M+39.2% | $9.1M+1.5% | $8.6M-4.8% | $8.2M-7.7% | $8.7M+2.6% | $9.0M+6.4% |
| Stock-Based Compensation | $28.9M+60.2% | $19.1M+47.4% | N/A | $14.9M+3.4% | $18.0M+59.3% | $13.0M+16.3% | N/A | $14.4M+37.5% |
| Capital Expenditures | $2.7M+132.2% | $4.0M+104.3% | $2.9M+68.1% | $1.6M+12.8% | $1.2M-45.1% | $1.9M+100.2% | $1.7M-58.9% | $1.4M-56.8% |
| Free Cash Flow | $12.1M+108.4% | -$16.5M+19.4% | $3.9M+420.5% | -$11.7M-6.2% | $5.8M+128.3% | -$20.5M+41.3% | -$1.2M+91.8% | -$11.0M+4.3% |
| Investing Cash Flow | -$5.3M+74.5% | $10.5M+128.4% | -$15.9M-234.8% | -$4.0M-113.1% | -$20.8M-159.6% | -$36.9M-25.7% | $11.8M+191.2% | $30.6M+105.2% |
| Financing Cash Flow | $991K-55.9% | $15.8M+708.7% | $2.4M-96.0% | $5.3M-45.6% | $2.2M-73.9% | $1.9M-85.2% | $60.1M+723.1% | $9.7M+29.5% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GKOS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.7%+3.3pp | 77.9%+0.7pp | 77.8%+4.9pp | 78.4%+1.8pp | 78.3%+1.9pp | 77.2%+0.9pp | 72.9%-4.2pp | 76.6%+0.4pp |
| Operating Margin | -9.3%+9.0pp | -13.2%+6.2pp | -97.7%-70.6pp | -12.3%+13.3pp | -18.3%+13.0pp | -19.4%+26.2pp | -27.2%+19.7pp | -25.5%+10.4pp |
| Net Margin | -9.9%+5.9pp | -13.1%+3.9pp | -93.4%-61.6pp | -12.2%+10.0pp | -15.8%+37.0pp | -17.0%+30.7pp | -31.8%+12.8pp | -22.1%+16.9pp |
| Return on Equity | -2.7%-0.1pp | -2.9%-0.6pp | -20.4%-16.0pp | -2.1%+1.1pp | -2.6%+5.0pp | -2.4%+6.7pp | -4.4%+3.6pp | -3.2%+3.2pp |
| Return on Assets | -2.0%0.0pp | -2.2%-0.3pp | -15.0%-11.5pp | -1.6%+0.7pp | -2.0%+3.5pp | -1.9%+2.5pp | -3.4%+0.5pp | -2.3%+0.9pp |
| Current Ratio | 5.04-0.5x | 5.43-1.1x | 4.69-1.3x | 5.20-0.3x | 5.510.0x | 6.49+1.1x | 5.99+0.6x | 5.54-0.4x |
| Debt-to-Equity | 0.35+0.1x | 0.33+0.1x | 0.36+0.1x | 0.30-0.1x | 0.29-0.1x | 0.26-0.8x | 0.27-0.8x | 0.39-0.6x |
| Asset Turnover | 0.20+0.1x | 0.17+0.1x | 0.16+0.1x | 0.130.0x | 0.130.0x | 0.110.0x | 0.110.0x | 0.100.0x |
| FCF Margin | 6.5%+1.8pp | -10.9%+8.2pp | 2.8%+3.9pp | -8.8%+2.6pp | 4.7%+26.1pp | -19.2%+21.5pp | -1.2%+16.9pp | -11.4%+3.4pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Glaukos Corporation GKOS | FY2025 | $507.4M | -$187.7M | -37.0% | $9.9B | 51/100 |
| Bruker Corp BRKR | FY2025 | $3.4B | -$8.3M | -0.2% | $8.3B | 44/100 |
| Transmedics Group TMDX | FY2025 | $605.5M | $190.3M | 31.4% | $3.0B | 57/100 |
| iRhythm Holdings, Inc IRTC | FY2025 | $747.1M | -$45.0M | -6.0% | $3.9B | 43/100 |
| Integer Hldgs Corp ITGR | FY2025 | $1.9B | $102.8M | 5.5% | $4.3B | 59/100 |
| Globus Med Inc GMED | FY2025 | $2.9B | $537.9M | 18.3% | $10.0B | 77/100 |
Where Glaukos Corporation Ranks
Frequently Asked Questions
What is Glaukos Corporation's annual revenue?
Glaukos Corporation (GKOS) reported $507.4M in total revenue for fiscal year 2025. This represents a 32.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Glaukos Corporation's revenue growing?
Glaukos Corporation (GKOS) revenue grew by 32.3% year-over-year, from $383.5M to $507.4M in fiscal year 2025.
Is Glaukos Corporation profitable?
No, Glaukos Corporation (GKOS) reported a net income of -$187.7M in fiscal year 2025, with a net profit margin of -37.0%.
What is Glaukos Corporation's EBITDA?
Glaukos Corporation (GKOS) had EBITDA of -$161.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Glaukos Corporation's gross margin?
Glaukos Corporation (GKOS) had a gross margin of 55.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Glaukos Corporation's operating margin?
Glaukos Corporation (GKOS) had an operating margin of -39.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Glaukos Corporation's net profit margin?
Glaukos Corporation (GKOS) had a net profit margin of -37.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Glaukos Corporation's return on equity (ROE)?
Glaukos Corporation (GKOS) has a return on equity of -28.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Glaukos Corporation's free cash flow?
Glaukos Corporation (GKOS) recorded an outflow of $22.5M in free cash flow during fiscal year 2025. This represents a 66.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Glaukos Corporation's operating cash flow?
Glaukos Corporation (GKOS) recorded an outflow of $14.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Glaukos Corporation's total assets?
Glaukos Corporation (GKOS) had $893.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Glaukos Corporation's capital expenditures?
Glaukos Corporation (GKOS) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Glaukos Corporation spend on research and development?
Glaukos Corporation (GKOS) invested $150.6M in research and development during fiscal year 2025.
What is Glaukos Corporation's current ratio?
Glaukos Corporation (GKOS) had a current ratio of 4.69 as of fiscal year 2025, which is generally considered healthy.
What is Glaukos Corporation's debt-to-equity ratio?
Glaukos Corporation (GKOS) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Glaukos Corporation's return on assets (ROA)?
Glaukos Corporation (GKOS) had a return on assets of -21.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Glaukos Corporation's P/E ratio?
Glaukos Corporation (GKOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $9.9B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Glaukos Corporation's price-to-sales ratio?
Glaukos Corporation (GKOS) trades at 16.1x sales, its market capitalization divided by revenue of $612.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $9.9B as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Glaukos Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Glaukos Corporation (GKOS) held $90.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $14.8M over that year. Dividing the one by the other, the reported balance equals about 74 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Glaukos Corporation's Altman Z-Score?
Glaukos Corporation (GKOS) has an Altman Z-Score of 23.81, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Glaukos Corporation's Piotroski F-Score?
Glaukos Corporation (GKOS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Glaukos Corporation's earnings high quality?
Glaukos Corporation (GKOS) reported a net loss of $187.7M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Glaukos Corporation cover its interest payments?
Glaukos Corporation (GKOS) reported an operating loss of $199.6M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Glaukos Corporation?
Glaukos Corporation (GKOS) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.